Literature DB >> 20021601

A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management.

Todd M Moore1, Ted Jones, Joe H Browder, Susan Daffron, Steven D Passik.   

Abstract

OBJECTIVE: The ability to predict risk for violating opioid medication policies, known as aberrant drug-related behavior, is critical for providing optimal treatment. Many pain management centers measure risk using one of several partially validated measures: the Screener and Opioid Assessment for Patients with Pain (SOAPP), the Diagnosis, Intractability, Risk, and Efficacy inventory (DIRE), and/or the Opioid Risk Tool (ORT). However, little is known about how these measures compare with each other in predicting aberrant drug-related behavior and discontinuance of opioid pain medications. The current study aimed to address this research question. PATIENTS: Participants were 48 patients who attended a pain management center in Tennessee but were later discontinued from opioids for aberrant drug-related behavior. Patients referred for opioid medication for pain management participated in a semi-structured clinical interview with the staff psychologist and completed the aforementioned measures. Patients generally returned to the pain clinic on a monthly basis for medication management. Results. Analyses compared the sensitivity of each self-report measure and the clinical interview in predicting discontinuance for aberrant drug-related behavior.
RESULTS: showed the highest sensitivity for the clinical interview (0.77) and the SOAPP (0.72), followed by the ORT (0.45) and the DIRE (0.17). Combining the clinical interview with the SOAPP increased sensitivity to 0.90.
CONCLUSIONS: Among patients who were discontinued from opioids for aberrant drug-related behaviors, the clinical interview and the SOAPP were most effective at predicting risk at baseline. Implications for future research and clinical practice are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20021601     DOI: 10.1111/j.1526-4637.2009.00743.x

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  40 in total

Review 1.  Lifestyle Medicine Interventions in Patients With Advanced Disease Receiving Palliative or Hospice Care.

Authors:  Gowri Anandarajah; Haran Asher Mennillo; Gregory Rachu; Tyler Harder; Jyotsna Ghosh
Journal:  Am J Lifestyle Med       Date:  2019-02-15

2.  Re-assessing the Validity of the Opioid Risk Tool in a Tertiary Academic Pain Management Center Population.

Authors:  Meredith R Clark; Robert W Hurley; Meredith C B Adams
Journal:  Pain Med       Date:  2018-07-01       Impact factor: 3.750

3.  Shortening the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R): A Proof-of-Principle Study for Customized Computer-Based Testing.

Authors:  Matthew D Finkelman; Ronald J Kulich; Kevin L Zacharoff; Niels Smits; Britta E Magnuson; Jinghui Dong; Stephen F Butler
Journal:  Pain Med       Date:  2015-07-14       Impact factor: 3.750

4.  Chronic opioid therapy for chronic pain: an e-learning program to develop shared decision-making and communication skills.

Authors:  Michael R Clark
Journal:  Curr Pain Headache Rep       Date:  2011-04

5.  Screening for substance abuse risk in cancer patients using the Opioid Risk Tool and urine drug screen.

Authors:  Joshua S Barclay; Justine E Owens; Leslie J Blackhall
Journal:  Support Care Cancer       Date:  2014-02-23       Impact factor: 3.603

Review 6.  Opioid Prescribing in an Opioid Crisis: What Basic Skills Should an Oncologist Have Regarding Opioid Therapy?

Authors:  Joseph Arthur; Akhila Reddy
Journal:  Curr Treat Options Oncol       Date:  2019-04-01

7.  Prescription Drug Monitoring Program Use: National Dental PBRN Results.

Authors:  J L McCauley; G H Gilbert; D L Cochran; V V Gordan; R S Leite; R B Fillingim; K T Brady
Journal:  JDR Clin Trans Res       Date:  2018-10-29

Review 8.  Review of the Current State of Urine Drug Testing in Chronic Pain: Still Effective as a Clinical Tool and Curbing Abuse, or an Arcane Test?

Authors:  Krishnan Chakravarthy; Aneesh Goel; George M Jeha; Alan David Kaye; Paul J Christo
Journal:  Curr Pain Headache Rep       Date:  2021-02-17

Review 9.  Management of pain with comorbid substance abuse.

Authors:  Daniel Krashin; Natalia Murinova; Jane Ballantyne
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

10.  Opioid misuse behaviors in adolescents and young adults in a hematology/oncology setting.

Authors:  Jennifer Harman Ehrentraut; Kathleen Danielle Kern; Sarah A Long; Angel Qi An; Lane G Faughnan; Doralina L Anghelescu
Journal:  J Pediatr Psychol       Date:  2014-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.